
|Videos|July 31, 2020
ASRS 2020: AsclepiX lead candidate holds potential for wet AMD, DME, RVO
Author(s)Alex Delaney-Gesing
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.
Advertisement
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis, during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Understanding fluid fluctuation in retinal disorders
2
FLORetina 2025: Reframing retinal disease through the lens of choroidal health
3
The gene therapy shift: A closer look at the science powering next-generation retinal treatments
4
Q&A: Veeral Sheth, MD, MBA, on personalized, imaging-centered geographic atrophy care
5













































